Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022

BACKGROUND: Immune checkpoint inhibitors (ICIs) combined with angiogenesis inhibitors (AGIs) have become increasingly available for multiple types of cancers, although the cardiovascular safety profiles of this combination therapy in real-world settings have not been elucidated to date. Therefore, w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yanfeng, Cui, Chanjuan, Deng, Lei, Wang, Lin, Ren, Xiayang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244526/
https://www.ncbi.nlm.nih.gov/pubmed/37292205
http://dx.doi.org/10.3389/fimmu.2023.1127128

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10244526/
https://www.ncbi.nlm.nih.gov/pubmed/37292205
http://dx.doi.org/10.3389/fimmu.2023.1127128

Ejemplares similares